Stock Financial Ratios, Dividends, Split History

AKRX / Akorn, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,343.58
Enterprise Value ($M)2,790.66
Book Value ($M)810.52
Book Value / Share6.47
Price / Book2.82
NCAV ($M)-347.94
NCAV / Share-2.78
Price / NCAV-5.62
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 124,790,000
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Common Shares Outstanding 125,258,177
Common Stock Shares Outstanding 125,090,522
Weighted Average Number Of Diluted Shares Outstanding 124,790,000
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.01
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.03
Balance Sheet (mrq) ($M)
Quick Ratio3.37
Current Ratio4.64
Income Statement (mra) ($M)
Sales Revenue Net841,045,000.00
Sales Revenue Goods Gross2,351,071,000.00
Sales Revenue Goods Net841,045,000.00
Operating Income-17.66
Net Income-24.55
Earnings Per Share Basic-0.20
Earnings Per Share Diluted-0.20
Cash Flow Statement (mra) ($M)
Cash From Operations249.26
Cash from Investing-90.56
Cash from Financing-90.56
Identifiers and Descriptors
Central Index Key (CIK)3116
Related CUSIPS
009728906 000972810 009728956

Split History

Stock splits are used by Akorn, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis

2018-06-13 seekingalpha
Mylan's approval of its Neulasta biosimilar derisks management's 2H guidance and, importantly, demonstrates the company's ability to bring complex generics to market. (160-0)

Akorn And Fresenius: Merger Arbitrage

2018-06-08 seekingalpha
A price cut in the range of $24-26 (~25-30% discount to original offer of $34) seems most likely but also can't rule out closing on terms. (19-0)

SA Interview: Event-Driven Investing With Donostia

2018-05-13 seekingalpha
Donostia is an analyst at an event-driven hedge fund who focuses on long/short ideas across the capital structure. (24-0)

Will Fresenius Now Also Abandon The NxStage Medical Deal?

2018-05-04 seekingalpha
In light of the Akorn-Fresenius merger fallout we take a look at the Fresenius-NXTM pending merger. (24-2)

Your Daily Pharma Scoop: Achaogen Mixed Ad Com, Esperion Mixed Results, InVivo Up On Old Data

2018-05-04 seekingalpha
So, the FDA Ad Com finally backed Achaogen’s (NASDAQ:AKAO) plazomicin! While that is good that the committee voted 15-0 (1 abstain) in favor of the cUTI indication, it is not so good that they also voted 11-4 (1 abstain) that that the the data failed to provide substantial evidence of the safety and efficacy of plazomicin in bloodstream infections in patients with limited or no treatment options. So they failed on that front, which is a smaller market than cUTI, but still enough of a downer to take the stock down 30% today. (129-2)

CUSIP: 009728106